Excited to be the keynote speaker and to meet all the grad students and postdocs at #2024MIKIW medicinal chemistry meeting-in-miniature in Chicago!!
mikiw2024.uic.edu/about-mikiw/

For the first time since 2017, all four of Annie's eggs have hatched in her nest on the Campanile. Congrats to Annie and Archie on their fluffy chicks! 🐣 CalFalconCam news.berkeley.edu/2024/04/24/new…

Delighted to see this work on the first inhibitor/degrader of the Werner Helicase (WRN), finally published. A genetically defined synthetic lethality, to be tested in the human model system of disease. Congratulations to all from NIBR who led this program. nature.com/articles/s4158…

⁦Vividion Therapeutics⁩ Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase | Nature nature.com/articles/s4158…

Why does the pharma industry do such a horrible job at communicating its value proposition and what could be done better? Some thoughts in this piece by ⁦Peter Kolchinsky⁩ rapport.bio/all-stories/er…

Today is a special day. Our multi-year study led by an AMAZING group of scientists Mariko Takahashi, Harrison Chong and Siwen Zhang comes out Cell. DrugMap: A quantitative pan-cancer analysis of cysteine ligandability. Check it out here: authors.elsevier.com/a/1izTCL7PXqQHi.

The CeTPD March 2024 CeTPD journal club issue is now live!

buff.ly/3W3qC6U

Thanks to our amazing editors:
Bharat Gadakh Natalia Karolak Roberta Ibba

#openaccess #TPD #journalclub UoD Life Sciences

Alessio Ciulli Will Farnaby Andreas holmqvist Aitana de la Cuadra Baste

Strawberry picking with this guy today! So much fun! Now time to eat them!

Human genetic evidence for target relevancy increases the probability of success in clinical trials, and there is still more room for improvement in the future – insights from Eric Minikel et al.

Letters of intent for our The Mark Foundation for Cancer Research early career grant (Emerging Leader Award) are due April 29th, more info here: themarkfoundation.org/emerging-leade…

Excited to be in Manhattan, Kansas today to present our latest research for the K. J. Klabunde Memorial Lecture in Chemistry ⁦K-State⁩ k-state.edu/today/announce…

Molecules of the Month – March 2024

Crinetics Pharmaceuticals revealed their discovery of CRN04894, a FIC nonpeptide MC2R antagonist which is currently being evaluated in several Ph. II trials.

Check out our other top molecules from March!

Article | drughunters.com/49BtrPC

USP7-Based Deubiquitinase-Targeting Chimeras Stabilize AMPK | Journal of the American Chemical Society pubs.acs.org/doi/10.1021/ja…

How to pick a problem. Today in Cell. 1/53
cell.com/cell/fulltext/…

Lab dinner celebrating all the 2nd yrs passing their quals!

First up in this session, Ryan Potts showed two nice examples of proximity induction that do not lead to degradation: a KIF18A-tubulin stabilizing molecular glue and a 'LOCKTAC' that plugs up PRMT5 with MTA.

Awesome to have Rich Lyons as our new UC Berkeley Chancellor!!! Congrats Rich Lyons !!! news.berkeley.edu/2024/04/10/ric…

Excited about ⁦Frontier Medicines⁩ First-In-Class Dual ON+OFF KRAS G12C Inhibitor FMC-376 now in Phase I/II clinical trials!! frontiermeds.com/newsroom/press…

Interesting discovery of a FBXO22 glue, which is in line with the previous report (biorxiv.org/content/10.110…) where the primary amine is metabolized to an aldehyde. This then engages in the covalent modification of surface cysteine residues in FBXO22. Probably a similar MoA.

Fantastic talk by Elisia Villemure Genentech on how to turn BRM/BRG (SMARCA2/4) bromodomain inhibitors into monovalent degraders by generating & screening a small library of derivatives. This time it’s not DCAF16 doing the job but E3 ligase FBXO22 (CRL1 complex) #AACR24 #TPD